Case series examines glucocorticoid dose reduction and elimination in uncontrolled gout patients, suggesting feasibility.
Key Points
This study aims to investigate the feasibility of reducing or eliminating preinfusion glucocorticoids in uncontrolled gout patients treated with pegloticase and methotrexate.
Retrospective case series conducted in a single rheumatology practice from January 2020 to April 2023.
Patients receiving pegloticase with methotrexate underwent preinfusion methylprednisolone dose reduction or elimination.
Assessment included serum urate levels and safety evaluations of adverse events.
At 24 weeks, 83% of patients were responders (SU <6 mg/dL), and 75% maintained response post-GC reduction.
83% of patients experienced gout flares, while no infusion reactions were reported.
Patients received a mean of 14.3 pegloticase infusions, ceasing glucocorticoids after about 7.6 infusions.